Details
Stereochemistry | RACEMIC |
Molecular Formula | C9H10N2O.C4H4O4 |
Molecular Weight | 278.2607 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C(O)=O.NC1=NCC(O1)C2=CC=CC=C2
InChI
InChIKey=ZVAWZQUDKKABKR-WLHGVMLRSA-N
InChI=1S/C9H10N2O.C4H4O4/c10-9-11-6-8(12-9)7-4-2-1-3-5-7;5-3(6)1-2-4(7)8/h1-5,8H,6H2,(H2,10,11);1-2H,(H,5,6)(H,7,8)/b;2-1+
Aminorex is an anorectic stimulant drug. Aminorex inhibits norepinephrine and dopamine transporters with IC50 of 0.33 and 0.85 uM. It was briefly available as an appetite suppressant in the 1960s in Switzerland, Germany, and Austria, but was found to cause pronounced vasoconstriction in the pulmonary vasculature, and was withdrawn from the market in 1972 due to several cases of fatal and life-threatening pulmonary hypertension. In the USA aminorex is an illegal schedule I drug.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
[A case of chronic pulmonary hypertension after fenfluramine intake]. | 1982 Nov 26 |
|
Pulmonary hypertension and dexfenfluramine. | 1995 |
|
Aminorex, dexfenfluramine, and primary pulmonary hypertension. | 1998 Apr |
|
Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension. | 1998 Dec |
|
[Development of pulmonary hypertension and multi-valvular damage caused by appetite depressants]. | 1998 Dec 1 |
|
Two different drug-induced pulmonary complications in a patient suffering from rheumatoid arthritis. | 1998 May |
|
[Obesity: principles of drug therapy]. | 2000 Aug |
|
[Anorectics and pulmonary hypertension]. | 2000 Feb 16 |
|
Anorectic drugs and pulmonary hypertension from the bedside to the bench. | 2001 Apr |
|
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. | 2001 Jan |
|
[Drug induced pulmonary hypertension]. | 2001 Jun |
|
Risk factors for pulmonary arterial hypertension. | 2001 Sep |
|
Effects of anorexinogen agents on cloned voltage-gated K(+) channel hKv1.5. | 2001 Sep |
|
Anorexigen-induced pulmonary hypertension and the serotonin (5-HT) hypothesis: lessons for the future in pathogenesis. | 2002 |
|
[Pulmonary hypertension and obesity]. | 2002 Apr |
|
Therapeutic and adverse actions of serotonin transporter substrates. | 2002 Jul |
|
Appetite suppressants as agonist substitution therapies for stimulant dependence. | 2002 Jun |
|
Effects on serotonin in rat hypothalamus of D-fenfluramine, aminorex, phentermine and fluoxetine. | 2002 Jun 7 |
|
Noradrenergic modulation of ephedrine-induced hypophagia. | 2003 Apr |
|
A century of pulmonary hemodynamics. | 2004 Jul 15 |
|
Primary pulmonary arterial hypertension: a look back. | 2004 Jun 16 |
|
Safety of drug therapies used for weight loss and treatment of obesity. | 2006 |
|
Effects on weight reduction and safety of short-term phentermine administration in Korean obese people. | 2006 Oct 31 |
|
Temporal trends and drug exposures in pulmonary hypertension: an American experience. | 2006 Sep |
|
Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice. | 2008 Jun 3 |
|
Pharmacokinetics and effects of aminorex in horses. | 2008 May |
|
Pulmonary hypertension: therapeutic targets within the serotonin system. | 2008 Oct |
|
The formation of aminorex in racehorses following levamisole administration. A quantitative and chiral analysis following synthetic aminorex or levamisole administration vs. aminorex-positive samples from the field: a preliminary report. | 2009 Apr |
|
Aminorex and rexamino as metabolites of levamisole in the horse. | 2009 Apr 6 |
|
Review paper: Current strategies in the development of anti-obesity drugs and their safety concerns. | 2009 Jan |
|
The serotonin hypothesis of pulmonary hypertension revisited. | 2010 |
|
Pulmonary hypertension associated with use of phentermine. | 2010 Nov |
|
Levamisole: a dangerous new cocaine adulterant. | 2010 Sep |
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m1742
Created by
admin on Fri Dec 15 16:53:17 GMT 2023 , Edited by admin on Fri Dec 15 16:53:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB00466MIG
Created by
admin on Fri Dec 15 16:53:17 GMT 2023 , Edited by admin on Fri Dec 15 16:53:17 GMT 2023
|
PRIMARY | |||
|
WSK05IH80K
Created by
admin on Fri Dec 15 16:53:17 GMT 2023 , Edited by admin on Fri Dec 15 16:53:17 GMT 2023
|
PRIMARY | |||
|
16422-62-1
Created by
admin on Fri Dec 15 16:53:17 GMT 2023 , Edited by admin on Fri Dec 15 16:53:17 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
100000085177
Created by
admin on Fri Dec 15 16:53:17 GMT 2023 , Edited by admin on Fri Dec 15 16:53:17 GMT 2023
|
PRIMARY | |||
|
13425-22-4
Created by
admin on Fri Dec 15 16:53:17 GMT 2023 , Edited by admin on Fri Dec 15 16:53:17 GMT 2023
|
PRIMARY | |||
|
6433577
Created by
admin on Fri Dec 15 16:53:17 GMT 2023 , Edited by admin on Fri Dec 15 16:53:17 GMT 2023
|
PRIMARY | |||
|
C006559
Created by
admin on Fri Dec 15 16:53:17 GMT 2023 , Edited by admin on Fri Dec 15 16:53:17 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD